Home > Insider Trading > Filing (0001104659-16-139283)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1638287	Gemphire Therapeutics Inc.	GEMP	Pharmaceutical Preparations (2834)	472389984

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1673991	Kent P. Hawryluk	43334 Seven Mile Road Suite 1000 Northville MI 48167		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2016-08-10	7,457	$0.00	7,457	No	4	C	Indirect	Held by the P. Kent Hawryluk Revocable Trust
Common Stock	Acquisiton	2016-08-10	816	$6.71	8,273	No	4	J	Indirect	Held by the P. Kent Hawryluk Revocable Trust
Common Stock	Acquisiton	2016-08-10	23,616	$6.71	31,889	No	4	C	Indirect	Held by the P. Kent Hawryluk Revocable Trust
Common Stock	Acquisiton	2016-08-10	25,000	$10.00	56,889	No	4	P	Indirect	Held by the P. Kent Hawryluk Revocable Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	Held by the P. Kent Hawryluk Revocable Trust
No	4	J	Indirect	Held by the P. Kent Hawryluk Revocable Trust
No	4	C	Indirect	Held by the P. Kent Hawryluk Revocable Trust
No	4	P	Indirect	Held by the P. Kent Hawryluk Revocable Trust

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Convertible Preferred Stock	Disposition	2016-08-10	7,457	$0.00	7,457	$0.00
Common Stock	8% Convertible Subordinated Promissory Notes	Disposition	2016-08-10	0	$0.00	23,616	$6.71

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	32,062	Direct

Footnotes

The Series A Convertible Preferred Stock converted into shares of common stock, par value $0.001 per share (the "Common Stock"), of Gemphire Therapeutics Inc. (the "Company") on a one-for-one basis immediately prior to the closing of the Company's initial public offering and had no expiration date.
These shares are indirectly owned by the reporting person as trustee of the P. Kent Hawryluk Trust.
Represents shares of Common Stock issued for payment of accrued dividends on the Series A Convertible Preferred Stock.
The notes were issued in the original principal amount of $150,000. The outstanding principal and $8,378 of accrued interest on the notes automatically converted into shares of Common Stock immediately prior to the closing of the Company's initial public offering.